Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Multi-Omics of Aurora Inhibition Induced Polyploidy Reveals Mechanisms of Disease Relapse in MYC/BCL2-Addicted High Grade B-Cell Lymphoma

Shariful Islam, Andrew Paek, PhD, Michael Hammer, PhD, Savithri Rangarajan, PhD, Robert Ruijtenbeek, PhD, Laurence Cooke, MS, Eric Weterings, PhD, Daruka Mahadevan, MD PhD

Blood (2018) 132 (Supplement 1): 1572.

https://doi.org/10.1182/blood-2018-99-109975

Published: 2018

Journal Articles

RX-3117, a Novel Nucleoside Analog Targeting UCK2 Is Active Alone and Synergistic with Ibrutinib and Bendamustine in ABC and DH/DP- Diffuse Large B-Cell Lymphoma

Shariful Islam, Umar Zahid, MD, Laurence Cooke, MS, Young Bok Lee, Deog Joong Kim, Ely Benaim, MD, Daruka Mahadevan, MD PhD

Blood (2017) 130 (Supplement 1): 5196.

https://doi.org/10.1182/blood.V130.Suppl_1.5196.5196

Published: 2017

Journal Articles

Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab

Shariful Islam, MS, Wenqing Qi, PhD, Carla Morales, B.S., Laurence Cooke, M.S., Manjari Pandey, MD, Catherine M. Spier, MD, Daruka Mahadevan, MD PhD

Blood (2016) 128 (22): 5397.

https://doi.org/10.1182/blood.V128.22.5397.5397

Published: 2016

Journal Articles

Aurora Plus PI3K Inhibition Abrogates PD-L1 Induction in Peripheral T-Cell Non-Hodgkin Lymphoma

Daruka Mahadevan, MD PhD, Eric Vick, PhD, Bryan Huber, MD, Carla Morales, B.S., Laurence Cooke, M.S., Catherine M. Spier, MD, Wenqing Qi, PhD

Blood (2015) 126 (23): 1560.

https://doi.org/10.1182/blood.V126.23.1560.1560

Published: 2015

Journal Articles

The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin

Kelly Zullo, MS, Yige Guo, PhD, Laurence Cooke, B.A., Xavier Jirau Serrano, BS, Michael Mangone, PhD, Luigi Scotto, PhD, Jennifer E. Amengual, MD, Daruka Mahadevan, MD PhD, Owen A. O'Connor, MD PhD

Blood (2014) 124 (21): 4493.

https://doi.org/10.1182/blood.V124.21.4493.4493

Published: 2014

Journal Articles

SF1126, a Pan-PI3K Inhibitor Has Superior Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Wenqing Qi, PhD, Amy Stejskal, MA, Laurence Cooke, BA, Joseph R Garlich, PhD

Blood (2011) 118 (21): 2720.

https://doi.org/10.1182/blood.V118.21.2720.2720

Published: 2011

Journal Articles

Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma

Daruka Mahadevan, MD, PhD, Laurence Cooke, BA, Amy Stejskal, MA, Ann Manziello, BS, Carla Morales, Daniel O. Persky, MD, Richard I Fisher, MD, Thomas P. Miller, MD, Wenqing Qi, PhD

Blood (2011) 118 (21): 2721.

https://doi.org/10.1182/blood.V118.21.2721.2721

Published: 2011

Journal Articles

Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies.

Joseph R Garlich, PhD, Michael D Becker, Candace F Shelton, Wenqing Qi, PhD, Xiaobing Liu, Laurence Cooke, Daruka Mahadevan, MD, PhD

Blood (2010) 116 (21): 1783.

https://doi.org/10.1182/blood.V116.21.1783.1783

Published: 2010

Journal Articles

Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Laurence Cooke, BS, Xiaobing Liu, BS, Daniel Oscar Persky, MD, Catherine M. Spier, MD, Thomas P. Miller, MD, Wenqing Qi, PhD

Blood (2010) 116 (21): 3933.

https://doi.org/10.1182/blood.V116.21.3933.3933

Published: 2010

Journal Articles

Targeting Aurora Kinase in Aggressive B-Cell Non-Hodgkin's Lymphomas.

Daruka Mahadevan, MD, PhD, Wenqing Qi, Laurence Cooke, Xiabing Lui, Daniel Oscar Persky, MD, Lisa M. Rimsza, MD, Thomas P. Miller, MD

Blood (2009) 114 (22): 284.

https://doi.org/10.1182/blood.V114.22.284.284

Published: 2009

Journal Articles

AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

Vicky Lock, Laurence Cooke, Murray Yule, Neil T Thompson, K. Della Croce, John F Lyons, Matthew S Squires, Daruka Mahadevan

Blood (2008) 112 (11): 3161.

https://doi.org/10.1182/blood.V112.11.3161.3161

Published: 2008

Journal Articles

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

Matthew S. Squires, PhD, Ruth E. Feltell, BSc, Victoria Lock, Donna M. Smith, PhD, Jon E. Lewis, Jacqueline Higgins, Murray Yule, MD, Neil T. Thompson, PhD, Laurence Cooke, Kimiko D. Croce, Wenqing Qi, John F. Lyons, PhD, Daruka Mahadevan

Blood (2007) 110 (11): 3127.

https://doi.org/10.1182/blood.V110.11.3127.3127

Published: 2007

Journal Articles

CLL Transcript and Serum Profiling Identifies Distinct Oncogenic Pathways in Rai Stage Progression.

Daruka Mahadevan, MD, PhD, Thomas Klinkhammer, MD, Laurence Cooke, MS, Christopher Riley, BS, James Choi, MD, Shripad Sinari, Thomas P. Miller, MD, Catherine Spier, MD

Blood (2007) 110 (11): 4688.

https://doi.org/10.1182/blood.V110.11.4688.4688

Published: 2007

Journal Articles

Transcriptosome and Serum Cytokine Profiling of B-CLL Identifies Oncogenic Pathways in Pathogenesis and Survival.

James Choi, MD, Harinder Garewal, MD, PhD, Christopher Riley, BS, Laurence Cooke, BS, Thomas Klinkhammer, MD, Sirisha Maddipati, MD, Rohit Sud, MD, Catherine Spier, MD, Daruka Mahadevan, MD, PhD

Blood (2006) 108 (11): 4953.

https://doi.org/10.1182/blood.V108.11.4953.4953

Published: 2006

Journal Articles

Transcriptosome Profiling of B-CLL Identifies WNT-3A and ROR-1 as an Autocrine Mechanism in Cell Survival.

James Choi, MD, B. Simons, Chris Riley, T. Klinkhammer, Laurence Cooke, Catherine Spier, MD, R. Sud, Sean Hehn, MD, Harinder Garewal, MD, Daruka Mahadevan, MD

Blood (2005) 106 (11): 2116.

https://doi.org/10.1182/blood.V106.11.2116.2116

Published: 2005

NARROW

Multi-Omics of Aurora Inhibition Induced Polyploidy Reveals Mechanisms of Disease Relapse in MYC/BCL2-Addicted High Grade B-Cell Lymphoma

RX-3117, a Novel Nucleoside Analog Targeting UCK2 Is Active Alone and Synergistic with Ibrutinib and Bendamustine in ABC and DH/DP- Diffuse Large B-Cell Lymphoma

Alisertib-Induced Polyploidy and Senescence in DH/DP-DLBCL Is Abrogated By Synthetic Lethal Interactions with Ibrutinib and Rituximab

Aurora Plus PI3K Inhibition Abrogates PD-L1 Induction in Peripheral T-Cell Non-Hodgkin Lymphoma

The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin

SF1126, a Pan-PI3K Inhibitor Has Superior Preclinical Activity to CAL-101 a PI3K Delta-Specific Inhibitor in Aggressive B-Cell Non-Hodgkin's Lymphoma

Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma

Phase I Study of Novel Prodrug Dual PI3K/mTOR Inhibitor SF1126 In B-Cell Malignancies.

Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma

Targeting Aurora Kinase in Aggressive B-Cell Non-Hodgkin's Lymphomas.

AT7519, a Potent Multi-Targeted CDK Inhibitor, Is Active in CLL Patient Samples Independent of Stage

AT7519, a Potent CDK Inhibitor, Is Active in Leukemia Models and Primary CLL Patient Samples.

CLL Transcript and Serum Profiling Identifies Distinct Oncogenic Pathways in Rai Stage Progression.

Transcriptosome and Serum Cytokine Profiling of B-CLL Identifies Oncogenic Pathways in Pathogenesis and Survival.

Transcriptosome Profiling of B-CLL Identifies WNT-3A and ROR-1 as an Autocrine Mechanism in Cell Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only